This article requires a subscription to view the full text. You may purchase access to this article or login to access your subscription using the links below.
Abstract
A new liquid biopsy test can accurately detect aberrant cancer-associated methylation patterns from minute amounts of DNA shed into the bloodstream. Although prospective validation is still needed, two studies highlight the assay's potential to noninvasively classify brain and kidney tumors.
- ©2020 American Association for Cancer Research.
Log in using your username and password
Purchase access
You may purchase access to this article. This will require you to create an account if you don't already have one.
September 2020
Volume 10, Issue 9
Volume 10, Issue 9
Blood Test Catches Cancers That Shed Little DNA
Jump to section
Advertisement